SCHEDULE: Gilde Healthcare Reduces Stake in LAVA Therapeutics to 19.9%

Gilde Healthcare, a significant shareholder, has sold 174,678 common shares of LAVA Therapeutics N.V. in open market transactions, reducing its beneficial ownership to 19.9%.

Summary

• Gilde Healthcare, along with its affiliated entities, has filed an Amendment No. 1 to its Schedule 13D, reporting recent sales of LAVA Therapeutics N.V. common shares.
• Between October 8, 2025, and October 13, 2025, Gilde Healthcare sold a total of 174,678 Common Shares in open market transactions.
• The sales occurred at weighted average prices ranging from $1.5377 to $1.5727 per share, generating aggregate proceeds of approximately $271,019.51.
• Following these sales, Gilde Healthcare's beneficial ownership in LAVA Therapeutics N.V. stands at 5,246,492 Common Shares, representing approximately 19.9% of the outstanding shares.
• As of August 8, 2025, LAVA Therapeutics N.V. had 26,305,295 Common Shares outstanding.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to a significant institutional investor reducing its stake, which can be interpreted as a lack of confidence or a strategic exit, despite the remaining substantial ownership.

Negatives

• A significant institutional investor, Gilde Healthcare, has reduced its stake in LAVA Therapeutics N.V. by selling 174,678 common shares.
• The sales occurred at prices between $1.5377 and $1.5727 per share, which may indicate a lack of conviction or a strategic portfolio adjustment by the investor.

Risks

• The reduction in ownership by a major institutional investor like Gilde Healthcare could be perceived negatively by the market, potentially impacting investor confidence and share price.
• Further sales by Gilde Healthcare could exert downward pressure on the stock price due to increased supply and potential signaling of a negative outlook.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding LAVA Therapeutics N.V.'s future performance or strategic direction. It solely reports changes in beneficial ownership by Gilde Healthcare.

Industry Context

This filing primarily concerns a change in institutional ownership rather than operational or strategic developments for LAVA Therapeutics N.V. It does not provide specific insights into broader industry trends or competitive landscape, beyond the general context of venture capital investment in biotechnology.

Legal Proceedings

• None of the Reporting Persons have been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) during the past five years.
• None of the Reporting Persons have been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction that resulted in a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws, or finding any violation with respect to such laws, during the last five years.

Stakeholder Impact

• Shareholders: The reduction in Gilde Healthcare's stake could lead to decreased investor confidence and potential downward pressure on the stock price.
• Company Management: May need to address market concerns regarding the institutional investor's reduced position.

Key Dates

Recommendation

While a significant institutional investor reducing its stake is generally a negative signal, Gilde Healthcare still retains a substantial 19.9% ownership. This suggests they are not fully exiting their position but rather rebalancing or taking profits. Without further information on LAVA Therapeutics' operational performance or Gilde Healthcare's specific reasons for the sale, a 'hold' recommendation is appropriate. Investors should monitor future filings and company performance for clearer direction.

Keywords

LAVA Therapeutics, Gilde Healthcare, Schedule 13D/A, Share Sales, Institutional Ownership, Biotechnology, SEC Filing, Common Shares, Equity Stake